AI tool enhances cancer diagnosis by transforming standard tissue images

Mor­phic Ther­a­peu­tic saw its shares $MORF slide by 25% Fri­day to about $38 af­ter da­ta from a small Phase IIa tri­al showed its in­flam­ma­to­ry bow­el

Al­ly Bridge Group, whose re­cent suc­cess­es in­clude CG On­col­o­gy‘s eye-pop­ping IPO, said it pro­mot­ed two peo­ple to head up its pri­vate eq­ui­ty strate­gies across biotech